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Hepatitis C virus (HCV)–related cirrhosis and 
hepatocellular  carcinoma  are  leading  indica-
tions  for  liver  transplantation  (LT).  A  major 
limitation is the universal HCV reinfection of 
the graft followed by an accelerated course   
of virus-induced liver disease (Brown, 2005).   
A  prophylactic  strategy  for  prevention  of   
reinfection  is  lacking,  and  interferon-based   
antiviral  therapies  have  limited  efficacy  and   
tolerability in LT recipients (Brown, 2005). Thus, 
recurrent liver disease with poor outcome has   
become an increasing problem facing hepatol-
ogists and transplant surgeons, underlying the 
urgent need for novel strategies for prevention 
of reinfection.
The  development  of  preventive  antiviral 
strategies has been hampered by a limited un-
derstanding of the mechanisms leading to HCV 
reinfection.  Reinfection  occurs  within  a  few 
hours of graft reperfusion despite the presence 
of anti-HCV antibodies (Brown, 2005). Evolu-
tion of viral quasispecies rapidly changes after 
transplantation, and only a small fraction of viral 
variants present before transplantation is selected 
after LT (Moreno Garcia et al., 2003; Feliu   
et  al.,  2004;  Brown,  2005;  Schvoerer  et  al., 
2007).  These  observations  suggest  that  HCV 
has developed efficient strategies to evade host 
immunity and adapt rapidly to the new host en-
vironment.  The  mechanisms  by  which  viral 
variants are selected and HCV evades host im-
munity to establish persistence in transplanted 
patients are not understood.
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End-stage liver disease caused by chronic hepatitis C virus (HCV) infection is a leading 
cause for liver transplantation (LT). Due to viral evasion from host immune responses and 
the absence of preventive antiviral strategies, reinfection of the graft is universal.  
The mechanisms by which the virus evades host immunity to reinfect the liver graft are 
unknown. In a longitudinal analysis of six HCV-infected patients undergoing LT, we  
demonstrate that HCV variants reinfecting the liver graft were characterized by efficient 
entry and poor neutralization by antibodies present in pretransplant serum compared with 
variants not detected after transplantation. Monoclonal antibodies directed against HCV 
envelope glycoproteins or a cellular entry factor efficiently cross-neutralized infection of 
human hepatocytes by patient-derived viral isolates that were resistant to autologous  
host-neutralizing responses. These findings provide significant insights into the molecular 
mechanisms of viral evasion during HCV reinfection and suggest that viral entry is a viable 
target for prevention of HCV reinfection of the liver graft.
© 2010 Fafi-Kremer et al.  This article is distributed under the terms of an At-
tribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After   
six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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mechanisms of viral evasion during HCV reinfection and 
suggest that viral entry is a viable target for the prevention of 
HCV reinfection of the liver graft.
RESULTS
Composition and diversity of HCV variants before  
and after LT
To study the impact of viral entry and neutralization on viral 
evasion during LT, we investigated viral quasispecies evolu-
tion in six patients infected with HCV genotype 1b undergo-
ing LT (Table I). A total of 439 clones (mean, 24 per time 
point and patient; range, 20–31) was obtained by RT-PCR 
from serum before and 7 d and 1 mo after transplantation.   
To  investigate  the  evolutionary  dynamics  of  the  envelope 
quasispecies evolution, distribution of viral quasispecies was 
analyzed as described previously for other cohorts (Farci et al., 
2000; Feliu et al., 2004; Schvoerer et al., 2007).
Sequence analysis demonstrated the presence of different 
viral variants in the serum before and after transplantation   
(Figs. 1 and 2 and Figs. S1 and S2). Several variants (e.g., VA to VK 
in patient 01) were not detected after transplantation (termed 
nonselected variants), whereas other variants (termed selected 
variants) were detected both before and after transplantation 
and were the predominant viral isolates after transplantation 
(e.g., variant VL in patient 01; Fig. 2). Phylogenetic analyses of 
viral sequences detected before and 7 d after transplantation   
revealed a marked and abrupt decrease of diversity (bottleneck 
effect) at day 7 in four out of six patients (P01, P02, P03,   
and P06), with selected variants clustering in a single branch 
(Fig. 1). The viral diversity in the other two patients (P04 and 
P05), which was low before transplantation, remained stable 
before and after transplantation (Fig. 1).
Compared with the marked decrease in diversity of vari-
ants in the majority of patients immediately after transplanta-
tion (Fig. 1), the virus population remained homogeneous   
1 mo after transplantation (Fig. S1). The mean genetic distances 
between the sequences obtained at day 7 and those obtained 
at month 1 were 1%, 1%, <0.1%, 1.1%, 1.3%, and 4% for P01, 
P02, P03, P04, P05, and P06, respectively. Sequences isolated 
HCV has a very high replication rate, and the highly   
error-prone viral polymerase allows for rapid production of 
minor viral variants that may outpace humoral and cellular 
immune responses (Bowen and Walker, 2005; Ray et al., 
2005; von Hahn et al., 2007; Uebelhoer et al., 2008; Aurora 
et al., 2009; Dazert et al., 2009). These variants are under 
constant immune pressure in the infected host, and selection 
processes lead to domination of the viral quasispecies by   
the most fit virus that can also evade immune recognition 
(Uebelhoer et al., 2008).
Both viral and host factors are potential determinants for 
evasion from host responses and adaptation of the virus after 
transplantation. Viral entry is the very first step of HCV infec-
tion (Evans et al., 2007; Zeisel et al., 2007, 2008; von Hahn 
and Rice, 2008; Ploss et al., 2009) and is thus an important 
factor for initiation of infection of the naive liver graft. More-
over, viral entry is a major target of neutralizing antibodies, a 
first-line host defense inhibiting viral spread. Indeed, the rapid 
induction of cross-neutralizing antibodies in the very early phase 
of infection has been suggested to contribute to control of 
HCV infection (Lavillette et al., 2005; Pestka et al., 2007).
In this study, we aimed to investigate whether viral entry 
and escape from neutralizing antibodies are determinants for 
viral evasion and persistence during the very early phase of 
graft  infection.  Infectious  retroviral  HCV  pseudoparticles 
(HCVpps) have been shown to represent a robust and valid 
system for the study of HCV entry and antibody-mediated 
neutralization in clinical cohorts (Lavillette et al., 2005; 
Dreux et al., 2006; Pestka et al., 2007; Grove et al., 2008; 
Haberstroh et al., 2008; Zeisel et al., 2008; Witteveldt et al., 
2009). Using HCVpps bearing viral envelope glycoproteins 
derived from patients undergoing LT, we show that efficient 
viral entry and escape from antibody-mediated neutralization 
are key determinants for selection of viral variants reinfect-
ing the liver graft. Furthermore, we demonstrate that mAbs   
directed against viral or host entry factors efficiently cross-
neutralized  infection  of  human  hepatocytes  by  patient- 
derived  viral  isolates  that  were  resistant  to  autologous 
host-neutralizing responses. These results define the molecular 
Table I.  Clinical and virological features of HCV-infected patients undergoing LT
Patient number Age R/D Gender Indication of transplantation  
and MELD
HCV genotype Viral load IS treatment
BT D7 M1
yr log10 IU/ml log10 IU/ml log10 IU/ml
P01 60/73 Male Cirrhosis + HCC MELD 9.32 1b 5. 94 5.20 5.72 tac/cor
P02 34/65 Male Cirrhosis MELD 10.37 1b 5.14 4.18 5.14 tac/rap/cor
P03 64/74 Male Cirrhosis + HCC MELD 9.53 1b 5. 61 3.65 6.83 tac/rap/cor
P04 69/15 Female Cirrhosis + HCC MELD 23.59 1b 6.42 4.94 6.90 tac/rap/cor
P05 51/22 Male Cirrhosis MELD 14.25 1b 5.39 4.85 5.22 tac/cor
P06 65/68 Female Cirrhosis + HCC MELD 11.99 1b 5.96 6.19 6.90 tac/rap/cor
HCC, hepatocellular carcinoma; tac, tacrolimus; rap, rapamycin; cor, corticosteroids. Patient number, age of recipient (R) and donor (D), recipient gender, indication of 
transplantation, model of end-stage liver disease (MELD) score before transplantation, HCV genotype, viral load (before [BT] and day 7 [D7] and month 1 [M1] after 
transplantation), and immunosuppressive (IS) treatment are shown.JEM VOL. 207, August 30, 2010 
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Viral entry is important for selection 
of viral variants after LT
To determine the mechanism of se-
lection and evasion of viral variants 
during  reinfection,  we  produced 
HCVpps harboring full-length E1E2 
glycoproteins  of  all  detected  and 
grouped  variants  before  transplanta-
tion (nonselected variants; Figs. 1 and 2) 
as well as the most prevalent variants 
reinfecting  the  liver  graft  (selected 
variants; Fig. 2). Sequence analysis of 
viral isolates showed that 13 out of 63 isolates contained stop 
codons or insertions altering the open reading frame. These 
variants were not further analyzed for HCVpp production 
and are indicated by a number sign (#) in the respective pie 
charts of Fig. 2. Expression of envelope glycoproteins from 
33 out of 50 isolates (66%) resulted in the production of   
infectious HCVpps (Fig. 3). Complete sequences of isolates 
characterized in functional experiments are shown in Fig. S2. 
The strains reinfecting the graft always produced functional 
E1E2 (Fig. 3), whereas a large fraction of nonselected variants 
failed to produce infectious HCVpps (Fig. 3). The percent-
age  of  patient-derived  viral  isolates  resulting  in  infectious 
HCVpps was higher than in a recent longitudinal study of a 
at day 7 and month 1 after LT were clustered in the same 
branch of phylogenetic trees (Fig. S1), and variants selected at 
day 7 remained predominant 1 mo after transplantation in all 
patients (Fig. S1 and not depicted). Sequence analysis of serum 
samples at month 6 and 12 after transplantation available from 
three patients demonstrated that variants selected during the 
early phase of transplantation (P01VL, P04VE, and P06VI) had 
the same or similar envelope glycoprotein sequence as predom-
inant variants present at later time points after transplantation 
(unpublished data). These data indicate that the new host envi-
ronment leads to an abrupt and marked change in the composi-
tion and diversity of the viral quasispecies in the majority of 
patients, which remains relatively stable after transplantation.
Figure 1.  Phylogenetic analyses of viral 
quasispecies evolution before and 7 d  
after LT. Evolution of HCV variants before and  
7 d after LT. Rooted neighbor-joining trees of 
HCV HVR1 amino acid sequences from the six 
patients depicted in Table I are shown. Boot-
strap values are expressed as percentages per 
1,000 replicates. Only bootstrap proportions 
>70 are indicated. Sequences of variants iso-
lated before LT and not detected on day 7 
after transplantation are depicted as open 
black circles, sequences of variants isolated 
before LT and reinfecting the graft are de-
picted as open blue circles, and sequences 
isolated 7 d after LT are depicted as blue 
squares. Viral isolates used for functional 
analysis are indicated with capital letters.
Figure 2.  Evolution of HCV variants before and  
7 d after LT. Distribution of full-length E1E2 variants 
(mean number of clones per patient, 24; range, 20–31) 
depicted in Fig. 1 is shown for each patient. Circle 
graphs represent the percentage of each clone de-
tected. The number of each clone is indicated. Viral 
isolates are indicated by an individual color and capital 
letters. Variants containing stop codons, insertions, or 
deletions altering the HCV open reading frame are de-
picted with a number sign (#) and were not further 
analyzed in HCVpp assays. Variants reinfecting the liver 
graft are depicted in blue, and nonselected variants not 
detected after transplantation are depicted in white, 
gray, or black. BT, before LT; D7, 7 d after LT2022 Mechanisms of viral evasion during graft infection | Fafi-Kremer et al.
transplantation are characterized by more efficient entry com-
pared with isolates not detected after transplantation. Collec-
tively, these data suggest that the efficiency of viral entry into 
naive hepatocytes of the liver graft is important for selection of 
viral variants after LT.
HCV variants reinfecting the liver graft escape autologous 
neutralizing responses
Because viral entry is a major target of neutralizing antibodies 
and HCV reinfection of the liver graft occurs efficiently 
despite the presence of high titer of anti-HCV antibodies, 
we investigated whether neutralizing antibodies present in 
pretransplantation serum were able to neutralize infection 
of patient-derived HCVpps. Patient-derived HCVpps were 
preincubated with autologous pretransplantation serum, and 
their subsequent infection levels were quantified. As shown 
in Fig. 4, HCVpps derived from selected variants were only 
poorly neutralized by antibodies present in pretransplant   
serum (mean neutralizing titer, 1:69; range, 1:20 to 1:200). 
In contrast, HCVpps derived from HCV variants that were 
not detected after transplantation were efficiently neutralized 
by autologous host-neutralizing antibodies (mean neutraliz-
ing titer, 1:2,257; range, 1:200 to 1:6,400). The differences 
between neutralization of selected and nonselected variants 
were highly significant (P < 0.001). Furthermore, nonse-
lected isolates showing high infectivity (e.g., strains P01VA, 
P02VA, P02VD, and P06VD) were efficiently neutralized by 
autologous pretransplant serum as shown in Fig. 4. These 
data demonstrate that escape from antibody-mediated neu-
tralization represents an important mechanism for viral eva-
sion from host immunity during LT.
To ensure that the selected variants emerge because of a   
clear competitive advantage and not just by chance, we analyzed 
HCV infection in the chimeric liver uPA-SCID (urokinase-type 
single HCV-infected patient (von Hahn et al., 2007). This 
difference is most likely caused by virus-specific factors   
allowing different use of entry factors because we observed a 
large variation in the percentage of infectious isolates within 
the six patients (37–100%). Alternatively, technical factors 
such as the use of more permissive Huh7 cells may have re-
sulted in the isolation of more variants with more easily de-
tectable HCVpp infection in this study.
To address whether the efficiency of infection was differ-
ent in strains reinfecting the liver graft (selected variants) and 
strains not detected during the first days of LT (nonselected 
variants), we performed a comprehensive analysis of viral entry 
of all patient-derived HCVpps containing functional full-
length HCV envelope glycoproteins. As shown in Fig. 3, 
HCVpps generated from variants reinfecting the graft were 
characterized by more efficient entry into Huh7 cells com-
pared with HCVpps generated from nonselected variants that 
were not detected after transplantation (mean enhancement 
152-fold; P < 0.0001). To confirm the results obtained with 
Huh7 hepatoma cell lines, we infected primary human hepa-
tocytes  obtained  from  four  different  donors  with  patient- 
derived  HCVpps  from  selected  and  nonselected  variants. 
Infection efficiency was 10–100-fold lower in human hepato-
cytes, as indicated by the level of reporter gene expression in 
cells infected with the same HCVpp preparations. Similar to 
results obtained with hepatoma cells, HCVpps of the selected 
variants showed more efficient entry than HCVpps produced 
from the nonselected variants (Fig. S3). The difference in viral 
entry observed between selected and nonselected variants did 
not result from variations in transfection efficiency (Fig. 3), 
nor was it caused by impaired HCVpp assembly or release   
because  the  levels  of  envelope  glycoprotein  incorporation 
into different pseudoparticles were similar (Fig. S4). These re-
sults demonstrate that viral isolates that are selected during 
Figure 3.  Viral entry is important for selection of viral variants after LT. (A) Transfection efficiency was analyzed for each variant and control 
(Ctrl; empty vector without E1E2) by quantifying luciferase expression (expressed as normalized percentage of transfection efficiency based on the pre-
dominant selected variant). (B) Comparative analysis of viral entry of HCVpps containing full-length E1E2 functional envelope proteins from pretransplant 
variants in Huh7 cells depicted in Fig. 2. HCVpps bearing patient-derived HCV envelope glycoproteins were added to Huh7 cells, and infection was ana-
lyzed by luciferase reporter gene expression. Results are expressed in relative light units (RLU) plotted in a logarithmic scale. The threshold for a detect-
able infection in this system is indicated by dashed lines. The detection limit for positive luciferase reporter protein expression was 3 × 103 RLU/assay, 
corresponding to the mean ± 3 SD of background levels, i.e., luciferase activity of naive noninfected cells or cells infected with pseudotypes without HCV 
envelopes (Dimitrova et al., 2008). Background levels of the assay were determined in each experiment. Means ± SD from at least four independent ex-
periments (performed in triplicate) are shown. Statistically significant differences (repeated measures ANOVA) in HCVpp entry between the predominant 
selected strain and nonselected strains are indicated by asterisks (**, P < 0.001). Variants reinfecting the liver graft are depicted in blue, and nonselected 
variants not detected after transplantation are depicted in white, gray, or black.JEM VOL. 207, August 30, 2010 
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ratio of highly infectious subvariants compared with the less   
infectious ones was high (5:8) in HVR1 variants with a high 
infectivity phenotype (VL) and low in HVR1 variants with a 
low infectivity phenotype (the ratio of high to low infectivity 
subvariants was 2:4 for VA, 1:7 for VB, and 0:3 for VK sub-
variants). Most importantly, we demonstrate that all of the 
nonselected E1E2 subvariants exhibiting high infectivity were 
efficiently neutralized by autologous patient serum (e.g., sub-
variants VAs1 and VBs1 in Fig. S5). Finally, grouping of viral 
quasispecies  on  complete  envelope  glycoprotein  sequences   
with subsequent functional analysis of all individual full-length 
clones in patient 01 again demonstrated that selected strains 
were characterized by efficient viral entry and escape from neu-
tralizing responses, whereas nonselected strains exhibited a poor   
entry and neutralization phenotype (unpublished data). These 
analyses corroborate that phylogenetic grouping of full-length 
E1E2 genomes by HVR1 analysis is valid and allows a func-
tional analysis of full-length clones whose function is representa-
tive of the entire E1E2 quasispecies population. Collectively, 
these analyses confirm that entry and neutralization are impor-
tant factors for selection of viral variants during HCV reinfection 
in LT independent of the method of quasispecies grouping.
Mutations in CD81 binding domains of E2 confer enhanced 
viral entry
To  map  envelope  regions  mediating  enhanced  entry  and   
viral escape, we focused on an individual patient (P01) and 
exchanged four regions spanning aa 221–483 (C-terminal E1 
plasminogen  activator/severe  combined  immunodeficient) 
mouse model after injection with pretransplant serum of patient 
P01 (Meuleman et al., 2008). As shown in Fig. 5, variant P01VL 
(which was selected after LT in the respective patient) was the 
most prevalent variant in both plasma and liver of the infected 
uPA-SCID mouse. This result corroborates the presumed selec-
tive advantage of the variant reinfecting the graft and demon-
strates the relevance of our analysis and validity of the HCVpp 
model system for HCV infection in vivo.
Functional analysis of HVR1 (hypervariable region 1) 
subvariants confirms that phylogenetic grouping allows  
a representative functional analysis of full-length variants
Grouping of full-length E1E2 quasispecies (Figs. 1 and 2) was 
performed on HVR1 variation because quasispecies grouping 
based on HVR1 variation has been shown to be the most accu-
rate approach to study the evolutionary dynamics of the HCV 
quasispecies population (Farci et al., 2000; Feliu et al., 2004; 
Schvoerer et al., 2007). To address whether grouping of full-
length E1E2 genomes by HVR1 analysis results in selection of 
clones that are representative of the functional properties of the 
entire quasispecies population, we performed a functional anal-
ysis of all detected E1E2 subvariants (VA, VB, VK, and VL) 
containing the same HVR1 of patient P01. This approach al-
lowed us to address the question whether all the subvariants 
harboring the same HVR1 have the same level of infectivity 
and if not, what is the ratio of highly infectious subvariants 
compared with the less infectious ones. As shown in Fig. S5, the 
Figure 4.  Escape from antibody-mediated neutralization is a key determinant for selection of viral variants after LT. HCVpps were incubated 
with pretransplant anti-HCV–positive serum or control anti-HCV–negative serum (Ctrl) in serial dilutions for 1 h at 37°C. HCVpp–antibody complexes 
were then added to Huh7 cells, and infection was analyzed as described in Fig. 3. Calculation of neutralization and determination of background and 
thresholds for neutralization are described in Materials and methods. End point dilution titers are indicated for each variant. Dashed lines indicate the 
threshold for a positive neutralization titer corresponding to 1:40. Variants reinfecting the liver graft are depicted in blue, and nonselected variants not 
detected after transplantation are depicted in white, gray, or black. Means from at least four independent experiments (performed in triplicate) are shown. 
Statistically significant differences (repeated measures ANOVA) in neutralization between the predominant selected strain and nonselected strains are 
indicated by asterisks (**, P < 0.001). NI, noninfectious.2024 Mechanisms of viral evasion during graft infection | Fafi-Kremer et al.
envelope glycoproteins and were not caused by any technical 
artifacts or by impairment in HCVpp production. Sequence 
analysis of P01VC and P01VL showed five mutations in   
the E425–483 region (H434Q, A444T, N445H, G458S, and 
C478R), including one mutation in CD81 BDII (C478R; 
Fig. 6, Fig. S2, and Table S1). Analysis of the sequences en-
compassing  the  same  region  (aa  425–483)  in  the  other   
patients showed mutations in the majority of strains of all 
patients but one (P05; Fig. S2 and Table S1). This finding 
suggests that mutations in this region are also involved in   
enhanced entry and sensitivity to neutralization in the other   
patients. Interestingly, nonselected variants exhibiting a low 
entry phenotype very frequently showed mutations in CD81 
binding domains I, II, and III (Table II and Fig. S2). Collec-
tively, these data support a model whereby acquired muta-
tions alter envelope glycoprotein–CD81 binding, which 
subsequently modulates the entry phenotype.
Sequence analysis of P01VB and P05 variants did not re-
veal any amino acid mutations within aa 425–483 or the three 
CD81 binding domains. The absence of mutations within 
these regions suggests that in these variants, other envelope 
regions are responsible for the alteration of the entry and neu-
tralization phenotype (Table II, Fig. S2, and Table S1). These 
could include SR-BI (scavenger receptor B I) binding sites 
within HVR1 (Fig. S2) or functional regions that contribute 
to viral entry steps mediated by claudin-1 or occludin. Inter-
estingly, a further analysis of the full-length E1E2 sequences of 
low entry variants P05VB and P05VC variants identified two 
mutations of cysteine residues at positions C229R and C564R, 
respectively. Structural modeling suggests that these mutations 
may alter disulfide bond formation, resulting in altered enve-
lope glycoprotein folding (Krey et al., 2010).
Cross-neutralizing mAbs efficiently inhibit entry of escape 
variants resistant to host responses
To investigate whether targeting entry of viral isolates infecting 
the liver graft by cross-neutralizing mAbs is a suitable approach 
for prevention of HCV reinfection, we incubated patient-
  derived HCVpps with mAb AP33 directed against an epitope 
within the HCV E2 protein and studied its ability to neutralize 
patient-derived HCVpps. As shown in Fig. 7 (A and B), anti-E2 
mAb AP33 efficiently inhibited infection of HCVpps contain-
ing envelope glycoproteins from both selected and nonselected 
viral variants in Huh7 cells and primary human hepatocytes (IC50 
0.1–3.3 µg/ml). Similar results were obtained by preincubating 
hepatocytes with an mAb directed against the large extracellular 
loop of HCV entry factor CD81 (Fig. 7 C; Pileri et al., 1998). 
Efficient neutralization of HCV isolates having escaped auto-
logous neutralizing responses by cross-neutralizing antibodies   
suggests that targeting viral entry by mAbs is a promising strategy 
for preventing HCV reinfection of the liver graft.
DISCUSSION
In this study, we demonstrate for the first time that viral entry 
into hepatocytes and escape from host-neutralizing antibodies 
represent important mechanisms for selection of HCV variants 
and N-terminal E2), 221–357 (E1), 358–424 (E2-HVR1), 
and 425–483 (E2-HVR2) of the envelope glycoproteins of 
selected variant P01VL and nonselected variant P01VC of 
patient P01 (Fig. 6, A and B). The exchange of HVR1 of se-
lected and nonselected variants resulted in chimeric HCVpps 
(P01VCVL-HVR1)  with  higher  infectivity  than  HCVpps 
derived from the P01VC parental strain (Fig. 6 C). The ex-
change of the E2 region comprising aa 425–483 resulted in 
chimeric HCVpps (P01VCVL-HVR2) with the highest in-
fectivity and poor neutralization by the autologous pretrans-
plant serum, the phenotype of the selected variant (Fig. 6,   
C and D). These data indicate that mutations in the HCV 
envelope region E2425–483 predominantly mediate enhanced 
viral entry and escape from neutralizing antibodies during re-
infection of the liver graft in this patient. Furthermore, these 
data confirm that the observed differences in entry and neu-
tralization were indeed mediated by mutations in the viral 
Figure 5.  Evolution of HCV variants in the uPA-SCID mouse model 
infected with patient-derived pretransplant serum. A human liver–
chimeric mouse was challenged by intraperitoneal injection of pretrans-
plant serum of patient P01 (infectious dose administered, 3.3 × 105 IU) and 
sacrificed at week 3 after infection. HCV RNA was isolated and amplified by 
RT-PCR from liver and plasma as described previously (Schvoerer et al., 
2007). HCV isolates in plasma and liver samples were cloned and sequenced 
as described in Materials and methods (30 clones per sample in one animal). 
Circle graphs represent the percentage of each clone detected, and numbers 
of clones are shown. Variant VL, which was selected after LT in patient P01, 
was the most prevalent variant in both plasma and liver of the infected 
uPA-SCID mouse. Variants containing stop codons, insertions, or deletions 
altering the HCV open reading frame are depicted with a number sign (#).JEM VOL. 207, August 30, 2010 
Article
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findings define the molecular mechanisms of viral evasion dur-
ing HCV reinfection and pave the way for novel antiviral strat-
egies for prevention of HCV reinfection of the liver graft.
during HCV reinfection of the liver graft. Furthermore, we 
show that infection of strains selected during transplantation can 
be efficiently neutralized by broadly neutralizing mAbs. These 
Figure 6.  Mutations in envelope region E2425–483 mediate enhanced viral entry and escape from neutralizing antibodies. To map envelope regions 
mediating enhanced entry and viral escape, we exchanged four regions spanning C-terminal E1 and N-terminal E2, E1, E2- HVR1, and E2-HVR2 of the enve-
lope glycoproteins of selected variant VL and nonselected variant VC of patient P01 (see Figs. 2–4). These regions include aa 221–483, aa 221–357, aa 358–
424, and aa 425–483, respectively. (A) Deduced amino acid sequences of the exchanged region between P01VC (black) and P01VL (blue). Amino acid changes 
are indicated in red bold letters. (B) Construction of recombinant chimeric HCVpps P01VCVL221–483 and P01VLVC221–483, P01VCVL-E1 and P01VLVC-E1, P01VCVL-
HVR1 and P01VLVC-HVR1, and P01VCVL-HVR2 and P01VLVC-HVR2 by exchanging E1E2 envelope domain aa 221–483, aa 221–357, aa 358–424, and aa 425–
483, respectively, of nonselected variant VC (patient 01) depicted in white and escape isolate VL (patient 01) depicted in blue (see Figs. 2–4). HVR1 and HVR2 
are shown in orange, and CD81 binding domains (CD81 BD) are shown in green. Positions of E2 epitopes I and II are indicated (Zhang et al., 2007, 2009). The 
number of mutations within each region is shown. (C) Viral entry of HCVpps containing chimeric envelope proteins in Huh7 cells. HCVpps were incubated 
with Huh7 cells, and infection was analyzed as described in Fig. 3. Results are expressed in relative light units (RLU) plotted in a logarithmic scale. The thresh-
old for a detectable infection is 3 × 103 RLU and was determined as described in Fig. 3. (D) Neutralization of HCVpps by autologous pretransplant serum was 
performed as described in Fig. 4. End point dilution titers are indicated for each variant. Dashed lines indicate the threshold for a positive neutralization titer 
corresponding to 1:40. Calculation of neutralization and determination of threshold titers are described in Materials and methods. Chimeric HCVpps are de-
picted in dashed blue. Statistically significant differences (repeated measures ANOVA) in HCVpp entry or neutralization between VC and VL wild-type and 
mutant variants are indicated by asterisks (**, P < 0.001). Ctrl, negative control; MT, mutation.2026 Mechanisms of viral evasion during graft infection | Fafi-Kremer et al.
humoral and cellular immunity. Viral variants evade immune 
response by continuous generation of B and T cell escape vari-
ants (von Hahn et al., 2007), resulting in slow and progressive 
change in composition of viral quasispecies with coexistence   
of highly neutralized and escape viral variants (von Hahn et al., 
2007). In contrast, the early phase of the posttransplantation   
period is characterized by rapid de novo infection of naive 
Both viral and host factors may contribute to HCV reinfec-
tion during LT. Viral factors include efficiency of entry, replica-
tion, and production of progeny virus. Host factors include 
humoral and cellular responses, graft- or donor-related factors, 
and immunosuppressive therapy. The pretransplantation envi-
ronment is characterized by chronic HCV infection, where   
viral population is subjected to selective pressures from both 
Table II.  Mutations within CD81 binding domains of viral variants
Viral 
variants
CD81 BDI amino acid 
positions
CD81 BDII amino acid positions CD81 BDIII amino acid positions
412 414 416 420 474 475 476 477 478 479 480 481 492 521 522 524 528 531 533 537 538
P01VLa Q V T W Y A E S R S S D Q R S V T E K L L
P01VAa
P01VBb
P01VCb C K
P01VIb L
P01VKb P L F A E
P01VJc I P R L
P02VIa Q I T W Y A E P H D L G Q R S A N E E L I
P02VJa Q D R
P02VHa Q D R
P02VAa V D
P02VDa V D R
P02VBb L A D
P02VFc S R S D R
P02VGc V D R T
P03VCa K V T W Y A K P N S S D R R F A S E E L L
P03VAa Q E T
P03VBb E
P04VEa Q I T W Y A E P R S L D Q R F V N E E L L
P04VDa
P04VCb
P04VAb N K
P04VBb
P05VEa Q V T W Y T E P E A L D Q R F V S E E L L
P05VFa
P05VDa
P05VAc
P05VBc
P05VCc
P06VHa Q I T W H V V P H G L D R R F A T E E F I
P06VIa R
P06VDa Q
P06VGb A R
P06VFb Y A E S R S V N L L
P06VAc Y A E R S
P06VBc Y A E R S V N L L
P06VCc
BD, binding domain; RLU, relative light unit. For each patient, amino acid changes in the CD81 BDI, BDII, and BDIII (Owsianka et al., 2006) relative to the most prevalent 
variant showing efficient viral entry are indicated. Amino acid positions where at least one mutation was observed in the six patients are shown; conserved amino acid 
positions are not depicted.
aVariants showing high infectivity (RLU ≥ 5 log10).
bVariants showing low infectivity (5 log 10 ≥ RLU ≤ 3.5 log10).
cNoninfectious variants (RLU ≤ 3 log10).JEM VOL. 207, August 30, 2010 
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uPA-SCID  mouse. 
This result corrobo-
rates the presumed 
selective advantage 
of the variant rein-
fecting the graft and 
confirms that the abrupt change of the host environment leads 
to selection of viral variants with an efficient entry phenotype.
The key impact of escape from neutralization is underlined 
by the finding that all nonselected variants, including isolates 
showing high infectivity (e.g., strains P01VA, P02VA, P02VD, 
and P06VD), were efficiently neutralized by autologous pre-
transplant serum and that all selected variants, including isolates 
with a lower infectivity phenotype (P02VH, P04VC, P06VG, 
P06VH, and P06VI), escaped neutralization (Figs. 3 and 4).
Interestingly, in all patients undergoing LT, the strains having 
escaped host immune responses after transplantation were also 
among the most prevalent strains before transplantation (Figs.   
2–4). These findings indicate that efficient entry and evasion 
from neutralizing responses result already in a survival advantage 
of the virus in the patient with end-stage liver disease and suggest 
that preselection of strains occurs already before transplantation. 
Nevertheless, the marked and abrupt homogenization of quasi-
species observed in phylogenetic analyses (Fig. 1), the stability of 
variants after transplantation (Fig. S1), and the relative advantage 
of selected variants in the uPA-SCID mouse model (Fig. 5) sug-
gest that the identified shifts in the viral populations with selec-
tion of neutralization-resistant and entry-efficient variants are 
related to the reinfection situation and do not simply represent 
processes that occur continuously during chronic infection.
hepatocytes in a host with impaired cellular immune responses. 
As shown by phylogenetic analyses (Fig. 1), this change of host 
environment results in an abrupt and marked change in the 
composition of viral quasispecies population. Phylogenetic 
analyses demonstrated a decrease in the quasispecies diversity 
after LT, with selection of only a fraction of relatively homoge-
neous viral variants in the majority of patients (Fig. 1). Thus, it is 
likely that the implantation of the new liver and start of immuno-
suppressive therapy generate a bottleneck effect by selecting 
variants that are able to infect the liver graft more efficiently. 
Because viral entry is a key determinant for the efficient and 
rapid initiation of viral infection and neutralizing antibodies are 
a first-line host defense in the transplanted liver, the ability of a 
viral isolate to efficiently infect naive hepatocytes and escape 
host-neutralizing responses may be an important advantage for 
the initiation of graft infection, allowing rapid dissemination of 
the virus. Indeed, the functional investigation of entry and neu-
tralization  of  patient-derived  viral  particles  before  and  after 
transplantation demonstrates that viral variants selected during 
transplantation were characterized by more efficient viral entry 
and escape from neutralizing antibodies compared with viral 
variants not detected after transplantation. This suggests that 
entry and evasion from antibody-mediated neutralization play a 
key role for selection of viral variants in the early phase of trans-
plantation. The concept that the selected variants emerge   
because of a clear competitive advantage and not just by chance 
is further supported by the analysis of HCV infection in the 
chimeric liver uPA-SCID mouse model (Fig. 5): the variant 
which was selected after LT in the respective patient was the 
most prevalent variant in both plasma and liver of the infected 
Figure 7.  Cross-neutralization of escape 
variants infecting the liver graft by anti-
envelope and antireceptor mAbs. (A) Neu-
tralization of HCVpps from viral isolates by 
cross-neutralizing anti-E2 mAb AP33. HCVpps 
derived from different isolates were incubated 
with 10 µg/ml anti-E2 AP33 or isotype mono-
clonal control IgG, and neutralization of viral 
entry in Huh7 cells was determined as de-
scribed in Fig. 4 (entry in the presence of iso-
type monoclonal control IgG = 100%). 
Neutralization was calculated as described in 
Materials and methods. Means ± SD from 
three independent experiments (performed in 
triplicate) are shown. (B and C) Neutralization 
of HCV isolates having escaped patients’ neu-
tralizing responses by anti-E2 and anti-CD81 
mAbs in primary human hepatocytes. HCVpps 
derived from viral isolates selected after LT 
(P01VL, P02VI, P03VC, P04VE, P05VF, and 
P06VI) were incubated with serial dilutions of 
anti-E2 AP33 (B) or control IgG from mouse 
(Ctrl) as described in Fig. 4 and then added to 
primary human hepatocytes. For analysis of 
neutralization using anti-CD81, primary  
human hepatocytes were preincubated with 
anti-CD81 or isotype control IgG for 1 h at 
37° before incubation with patient-derived 
HCVpps (C). Means from one representative 
experiment (performed in triplicate) out of 
two independent experiments are shown. 
50% neutralization of HCVpp entry is indi-
cated by a dashed line.2028 Mechanisms of viral evasion during graft infection | Fafi-Kremer et al.
Moreover, differences in neutralization remained similar when 
the amount of HCVpps for neutralization experiments was 
adjusted for relative infectivity or quantity of pseudoparticles 
(unpublished data).
Exchange of envelope domains of selected and nonse-
lected HCV variants demonstrated that mutations within the 
region E2425–483 mediate enhanced viral entry and escape from 
neutralizing antibodies. This region contains an important 
CD81 binding site (Owsianka et al., 2006) and is a target of 
patient-derived  neutralizing  antibodies  (Haberstroh  et  al., 
2008; Law et al., 2008). Thus, it is likely that the mutations 
present in this region enhance viral entry by modulating the 
affinity of E2 to CD81 and induce a conformational change 
allowing resistance to binding of neutralizing antibodies. Be-
cause the exchange of HVR1 of selected and nonselected 
HCV variants also resulted in a partial enhancement of viral 
entry (Fig. 6), it is likely that mutations in this region contrib-
ute to enhanced entry, e.g., by modulating SR-BI dependency 
(Bartosch et al., 2005).
It is of interest to note that the mapped E2 region confer-
ring escape from neutralizing antibodies (E2425–483) contains an 
epitope (epitope II, aa 434–446) recognized by host nonneu-
tralizing antibodies that have been proposed to disrupt virus 
neutralization by antibodies that target epitope I, a highly con-
served glycoprotein segment located upstream (aa 412–419; 
Zhang et al., 2007, 2009). Thus, the mutations identified in this 
epitope (e.g., H434Q, A444T, and N445H in variant VL; Fig. 6, 
Fig. S2, and Table S1) may enhance the binding of nonneutral-
izing antibodies and contribute to attenuation or escape from 
neutralization of selected variants by antibodies binding to epi-
tope I. However, it is noteworthy that neutralization of the se-
lected variants by our broadly neutralizing mAb AP33 (Fig. 7 B), 
which recognizes amino acid residues located in epitope I   
(Owsianka et al., 2005; Tarr et al., 2006), was not affected.
Collectively, our data suggest that adaptive mutations 
within  HVR1,  CD81  binding  domains,  and  neutralizing   
epitopes appear during HCV quasispecies evolution after LT, 
leading to the emergence of the most fit or best adapted virus 
that is resistant to host autologous neutralizing responses and 
that is capable of efficient de novo infection of the liver graft. 
The use of state of the art model systems, including patient-
derived HCVpps and naive human hepatocytes from different 
donors,  suggests  that  the  findings  obtained  indeed  mimic   
virus–host interactions occurring in the initiation of graft in-
fection in the HCV-infected patient. This is further supported 
by our in vivo experiments investigating viral evolution in the 
uPA-SCID mouse model repopulated with human hepato-
cytes and infected with pretransplant serum. The predominant 
variant which was selected after LT in the respective patient 
was the most prevalent variant in both plasma and liver of the 
infected uPA-SCID mouse (Fig. 5). These results demonstrate 
the relevance of our analysis and validity of the HCVpp model 
system for HCV infection in vivo. This is in line with the fact 
that in vitro neutralization in the HCVpp model system has 
been shown to reflect neutralization of infectious recombi-
nant cell culture–derived HCV in vitro (Lindenbach et al., 2005; 
Grouping of full-length E1E2 quasispecies (Figs. 1 and 2) 
was performed on HVR1 variation because quasispecies 
grouping based on HVR1 variation has been shown to be the 
most accurate approach to study the evolutionary dynamics of 
the HCV quasispecies population (Farci et al., 2000; Feliu   
et al., 2004; Schvoerer et al., 2007). The validity of this ap-
proach for our cohort was confirmed by a side by side com-
parison of phylogenetic analysis of HVR1 and full-length E1E2 
sequences: when HVR1 was excluded, the phylogenetic re-
constructions of the rest of the E1E2 region showed a mono-
phyletic population with absent discrimination between 
selected and nonselected variants similar to previous observa-
tions by Farci et al. (2000; and unpublished data). A functional 
analysis of entry and neutralization of variants containing the 
same HVR1 further corroborated that grouping of full-length 
E1E2 genomes by HVR1 analysis with subsequent functional 
analysis of full-length clones is valid and represents the func-
tional properties of the quasispecies population (Fig. S5).
It is conceivable that cell-mediated immune responses also 
contribute to the differences observed in variants before and   
after transplantation. Indeed, binding of envelope glycoprotein 
E2 to CD81 has been suggested to induce functional changes of 
natural killer or dendritic cells (Nattermann et al., 2006; Crotta 
et al., 2010). Because of the profound immunosuppression with 
severely impaired cell-mediated immune response after trans-
plantation, efficient viral entry most likely becomes the predom-
inant determinant of selection of viral variants in the transplanted 
host. The pretransplantation environment may allow nonse-
lected variants to compete with the selected variants despite dis-
advantages in terms of neutralizing antibody response and viral 
entry. In contrast, with immunosuppression after transplanta-
tion, which primarily impacts cell-mediated immunity, selected 
variants take over because efficient viral entry and escape from 
neutralizing responses give them a relative advantage. This hy-
pothesis is also supported by the experiments in the uPA-SCID 
mouse model: when the cell-mediated immune system is taken 
out of the equation, then viral entry becomes an important de-
terminant of relative fitness in the host (Fig. 5). Other factors 
may also contribute to relative viral fitness, including different 
replication abilities among HCV variants (Uebelhoer et al., 
2008; Dazert et al., 2009) or the ability to spread by cell–cell 
transmission (Timpe et al., 2008; Witteveldt et al., 2009).   
Finally, we cannot exclude the idea that mutations that improve 
virus entry will affect other steps of the viral life cycle.
The association of evasion of host-neutralizing responses 
and efficient entry may be explained by the fact that viral   
entry and neutralization are closely linked by the interference 
of neutralizing antibodies with envelope–host entry factor 
interactions. Indeed, we have previously shown that purified 
antiviral antibodies derived from HCV-infected patients in-
hibit HCV infection at an entry step closely linked to CD81 
and SR-BI interaction (Haberstroh et al., 2008). Neverthe-
less, escape from neutralization could not be explained simply 
by efficient viral entry because several variants with a high 
infectivity phenotype were also efficiently neutralized as shown 
in Figs. 3 and 4 (P01VA, P02VA, P02VD, and P06VD). JEM VOL. 207, August 30, 2010 
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Amplification and cloning of HCV E1E2. Total RNA was purified from 
280 µl of serum using the RNeasy kit (QIAGEN). cDNA was synthesized   
using superscript II reverse transcription (Invitrogen) with random primers 
(Invitrogen). The cDNA was used as the template for PCR amplification of 
the sequence encoding the C-terminal core and full-length E1E2 proteins   
using  HotStar  HiFidelity  PCR  Taq  polymerase  (QIAGEN)  and  primers 
MLVextS  (5-CGTAGGTCGCGTAACTTGGGTAA-3)  and  MLVextAS 
(5-GTGCGCCTCGGCTCTGGTGATAAA-3), corresponding to nt 
681–703 and 2886–2909, respectively. A nested PCR was performed using 
primers AD78-1 and -2 containing an EcoRV restriction site as described pre-
viously (Pestka et al., 2007). Full-length E1E2 PCR products were cloned into 
PCR 2.0-TOPO (Invitrogen). After sequencing (Beckman Coulter), cDNA 
containing the full-length E1E2 coding sequence was digested by EcoRV 
and  subcloned  into  expression  vector  pCMV-IRES  for  production  of 
HCVpps (Pestka et al., 2007). Phylogenetic analysis of viral quasispecies   
was performed as described previously (Schvoerer et al., 2007). Neighbor-
joining trees based on Kimura two-parameter distance matrices (1,000 boot-
strap resampling replications) were constructed using the MEGA 4 software 
package (Tamura et al., 2007; Schramm et al., 2008). Amino acid genetic di-
versity was based on the pairwise analysis of all the sequences within each 
time point.
HCVpp production, infection, and neutralization. HCVpps were gener-
ated by transfection of 293T cells as described previously (Bartosch et al., 2003; 
Pestka et al., 2007), using the CMV-Gag-Pol MLV (mouse leukemia virus) 
packaging construct, an MLV-Luc reporter plasmid, and the expression plas-
mids encoding the HCV envelope glycoproteins of HCV variants. To study 
HCV entry, HCVpps were added to Huh7 cells or primary human hepatocytes 
in triplicate and incubated for 72 h at 37°C. HCV entry was determined by 
analysis of luciferase reporter gene expression as described previously (von Hahn 
et al., 2007; Haberstroh et al., 2008). The detection limit for positive luciferase 
reporter protein expression was 3 × 103 RLU/assay corresponding to the 
mean ± 3 SD of background levels, i.e., luciferase activity of naive noninfected 
cells or cells infected with pseudotypes without HCV envelopes (Dimitrova   
et al., 2008). Background levels of the assay were determined in each individual 
experiment. For the study of antibody-mediated neutralization, HCVpps were 
mixed with autologous anti-HCV, anti-E2 mAb AP33, control serum (consist-
ing of a pool of three anti-HCV–negative sera), or irrelevant isotype control 
IgG and preincubated for 1 h at 37°C and added to Huh7 cells or primary   
human hepatocytes in triplicate for 72 h at 37°C (von Hahn et al., 2007). Anti-
CD81 mAb was preincubated with primary human hepatocytes for 1 h at 
37°C, and then HCVpps were added. Antibodies were serially diluted to deter-
mine the IC50, the concentration of antibody that gave a 50% inhibition of 
HCVpps. The specific neutralization was determined according to the fol-
lowing equation: specific neutralization = 100  [100 × (infectivity of 
HCVpps in the presence of autologous serum or mAb/infectivity of HCVpps 
in the presence of anti-HCV–negative control sera or irrelevant isotype con-
trol IgG)]. Background levels of HCVpp infection were taken into account 
by subtracting infectivity in the presence of control serum used at the same 
dilution as for autologous serum. The neutralization titer was defined as the 
last dilution of the sample that conveyed a ≥50% reduction of HCVpp entry 
compared with an equivalent dilution of control serum, as described pre-
viously (Pestka et al., 2007). Background of neutralization of HCVpp   
infection was determined by analysis of a large reference panel of anti-
HCV–negative control sera exhibiting a neutralization titer of ≤1:20. Thus, 
a neutralization titer of 1:40 was defined as the threshold of positive antibody-
mediated neutralization.
HCVpp infection of primary human hepatocytes. Primary human 
hepatocytes were isolated as described previously (Krieger et al., 2010). 
Primary hepatocytes were infected with HCVpps expressing envelope gly-
coproteins of predominant viral isolates described in Fig. 2. 1 d after hepa-
tocyte isolation and plating, hepatocytes were washed, and HCVpps were 
added for 3 h at 37°C. After infection, the supernatant was removed and 
replaced by fresh William’s E medium. HCVpp infection was assessed by 
Wakita et al., 2005; Zhong et al., 2005; Haberstroh et al., 
2008; von Hahn and Rice, 2008; Krieger et al., 2010) and in 
human hepatocytes in vivo (Law et al., 2008; Vanwolleghem 
et al., 2008). Furthermore, the HCVpp system is characterized 
by high robustness (von Hahn and Rice, 2008; Zeisel et al., 
2008) and efficient infection of human hepatocytes (Krieger   
et al., 2010) and allows the production of a large number of 
patient-derived viruses. Nevertheless, we cannot exclude the 
idea that the HCVpp system may or may not mimic all of the 
complexities of an authentic virus when it comes to neutral-
ization and entry.
Finally, our findings have important implications for the 
development of novel preventive strategies and management 
of the HCV-infected patient undergoing LT. It is of interest 
to note that first generation anti-HCV Ig or antibodies failed 
to prevent HCV recurrence after LT in clinical trials (Davis   
et al., 2005; Schiano et al., 2006). The reason why these anti-
bodies failed was most likely their poor neutralizing capacity. 
Indeed, in vitro and in vivo characterization of anti-E2 HCV-
AbXTL68 in preclinical experiments had shown an inefficient 
neutralization in the HCVpp model system and HCV-Trimera 
mouse model (Eren et al., 2006). Very recent studies in an 
HCV animal model have shown that new generation cross-
neutralizing anti-E2 or anti-CD81 antibodies are capable of 
neutralizing genetically diverse HCV isolates and protect 
against heterologous HCV quasispecies challenge (Law et al., 
2008; Meuleman et al., 2008). Our study demonstrates for the 
first time that cross-reactive mAbs neutralize infection of the 
liver graft by viral variants that are resistant to host-neutralizing 
responses and as such paves the way for the development of 
novel preventive strategies and improved management of the 
HCV-infected patient undergoing LT. Efficient inhibition of 
infection of diverse HCV escape variants studied here suggests 
that antireceptor or antienvelope mAbs will have sufficient cross- 
reactivity to neutralize highly variable quasispecies variants. 
Combination of antienvelope and antireceptor antibodies may 
further increase the genetic barrier for resistance and may offer 
a viable and promising strategy to prevent HCV reinfection of 
the liver graft.
MATERIALS AND METHODS
Patients. Clinical and virological features of patients followed at the Stras-
bourg University Hospitals are shown in Table I. Blood samples were col-
lected before and 7 d and 1 mo after LT with approval of the Strasbourg 
University  Hospital  Institutional  Review  Board  (http://clinicaltrials.gov 
identifier: NCT00213707). Anti-HCV antibodies and HCV RNA were an-
alyzed using AxSYM (Abbott) and VERSANT HCV RNA 3.0 (Bayer).
Cells and reagents. 293T cells and Huh7 cells were isolated and cultured 
as described previously (Pestka et al., 2007; Haberstroh et al., 2008). Pri-
mary human hepatocytes from liver resections were provided by P. Bachellier 
and D. Jaeck (Hôpitaux Universitaires de Strasbourg, Strasbourg, France) 
and isolated by C. Royer (Institut National de la Santé et de la Recherche 
Médicale, Unité 748, Strasbourg, France) as described previously (Krieger 
et al., 2010). Anti-E1 (11B7) and anti-E2 (AP33; 3E5-1) mAbs and human 
anti-HCV IgG have been described previously (Owsianka et al., 2005; 
Pestka et al., 2007; Haberstroh et al., 2008). Anti-CD81 (JS81) was ob-
tained from BD.2030 Mechanisms of viral evasion during graft infection | Fafi-Kremer et al.
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measurement of luciferase activity 72 h after infection, as described previ-
ously (Krieger et al., 2010).
Analysis of HCVpp envelope glycoprotein expression. Expression 
of HCV glycoproteins of predominant strains was characterized in 293T 
producer cells, and HCVpps were purified by sucrose gradient ultracentri-
fugation as described previously (Bartosch et al., 2003; Barth et al., 2006; 
Haberstroh et al., 2008). Immunoblots of HCV glycoproteins were per-
formed using antienvelope antibodies (anti-E1 mAb 11B7 and anti-E2 
mAb AP33 or 3E5-1) or anti-HCV IgG as described previously (Pestka   
et al., 2007).
Mapping of envelope domains mediating enhanced entry and es-
cape from neutralization. For mapping experiments, four major frag-
ments comprising the entire E1E2-coding region were exchanged between 
the selected variant P01VL and the nonselected variant P01VC of patient 
P01. These regions included aa 221–483, aa 221–357, aa 358–424, and aa 
425–483 and correspond to the functional regions E1, HVR1, HVR2, and 
CD81 binding domain II, respectively (Fig. 6, A and B). To allow the ex-
change, new restriction sites were generated by introducing silent muta-
tions  using  QuikChange  II  XL  (Agilent  Technologies).  The  resulting 
expression constructs encoding for P01VC/VL chimeric envelope glyco-
proteins were used to generate HCVpps as described previously (Pestka   
et al., 2007).
Infection of uPA-SCID mice transplanted with human hepatocytes. 
Human liver–uPA-SCID mice were infected with patient serum (P01), and 
viral quasispecies were analyzed as described previously (Law et al., 2008; 
Meuleman et al., 2008).
Statistical analysis. Statistical analysis (repeated measures analysis of vari-
ance [ANOVA]) was performed with the SPSS 16.0 software for Windows 
(SPSS Inc.).
Online supplemental material. Fig. S1 shows phylogenetic analyses of 
viral quasispecies evolution in the early phase posttransplantation (day 7 and 
month 1). Fig. S2 shows comparative alignment of amino acid sequences 
of full-length E1E2 variants isolated from the six transplanted patients and 
analyzed in functional experiments. Fig. S3 shows infection of primary   
human hepatocytes by HCVpps bearing envelope glycoproteins from the 
most prevalent selected and nonselected strains. Fig. S4 shows expression of 
envelope glycoproteins in 293T producer cells and HCVpps. Fig. S5 shows 
functional analysis of subvariants containing the same HVR1 in an indi-
vidual patient. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20090766/DC1.
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